<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang C</submitter><funding>Basic Research Project of Henan Eye Institute</funding><funding>Basic Research Project of the Henan Eye Institute</funding><funding>National Natural Science Foundation of China</funding><funding>Health science and Technology Innovation Outstanding Young talents training program of Henan Province</funding><funding>Health Science and Technology Innovation Outstanding Young Talents Training Program of Henan Province</funding><pagination>158</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10970420</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(3)</volume><pubmed_abstract>Age-related macular degeneration (AMD) is an ocular disease that leads to progressive photoreceptor death and visual impairment. Currently, the most common therapeutic strategy is to deliver anti-vascular endothelial growth factor (anti-VEGF) agents into the eyes of patients with wet AMD. However, this treatment method requires repeated injections, which potentially results in surgical complications and unwanted side effects for patients. An effective therapeutic approach for dry AMD also remains elusive. Therefore, there is a surge of enthusiasm for the developing the biodegradable drug delivery systems with sustained release capability and develop a promising therapeutic strategy. Notably, the strides made in hydrogels which possess intricate three-dimensional polymer networks have profo</pubmed_abstract><journal>Gels (Basel, Switzerland)</journal><pubmed_title>Hydrogel-Based Therapy for Age-Related Macular Degeneration: Current Innovations, Impediments, and Future Perspectives.</pubmed_title><pmcid>PMC10970420</pmcid><funding_grant_id>No. 82101162</funding_grant_id><funding_grant_id>YXKC2021027</funding_grant_id><funding_grant_id>No. 21JCQN002 and 21JCZD002</funding_grant_id><funding_grant_id>No. YXKC2021027</funding_grant_id><funding_grant_id>82101162</funding_grant_id><funding_grant_id>21JCZD002</funding_grant_id><funding_grant_id>21JCQN002</funding_grant_id><pubmed_authors>Fan W</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Wei D</pubmed_authors><pubmed_authors>Tao Y</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Song Z</pubmed_authors><pubmed_authors>Wu H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hydrogel-Based Therapy for Age-Related Macular Degeneration: Current Innovations, Impediments, and Future Perspectives.</name><description>Age-related macular degeneration (AMD) is an ocular disease that leads to progressive photoreceptor death and visual impairment. Currently, the most common therapeutic strategy is to deliver anti-vascular endothelial growth factor (anti-VEGF) agents into the eyes of patients with wet AMD. However, this treatment method requires repeated injections, which potentially results in surgical complications and unwanted side effects for patients. An effective therapeutic approach for dry AMD also remains elusive. Therefore, there is a surge of enthusiasm for the developing the biodegradable drug delivery systems with sustained release capability and develop a promising therapeutic strategy. Notably, the strides made in hydrogels which possess intricate three-dimensional polymer networks have profo</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2025-04-21T21:28:54.299Z</modification><creation>2025-04-05T18:22:24.241Z</creation></dates><accession>S-EPMC10970420</accession><cross_references><pubmed>38534576</pubmed><doi>10.3390/gels10030158</doi></cross_references></HashMap>